Efficacy Studies

Kennedy Halts $500 Million in mRNA Vaccine Contracts, Shifts Investment to Alternative Platforms

Citing failure of mRNA vaccines against upper respiratory infections, he redirected resources toward broader vaccine platforms beyond mRNA.